Results 171 to 180 of about 2,425,230 (388)

Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis?

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim   +5 more
wiley   +1 more source

Glucocorticoid receptor control of transcription: precision and plasticity via allostery

open access: yesNature reviews. Molecular cell biology, 2017
E. Weikum   +3 more
semanticscholar   +1 more source

Expert perspective: How, When, and Why to Potentially Stop Anti‐resorptive Drugs in Osteoporosis

open access: yesArthritis &Rheumatology, Accepted Article.
Osteoporosis is a chronic disease and anti‐resorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used anti‐resorptive treatments bisphosphonates and denosumab have short and longer term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G Saag
wiley   +1 more source

Time‐dependent effect of prophylactic trimethoprim‐sulfamethoxazole on the incidence of serious infections in ANCA‐associated vasculitis: A target trial emulation study

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives To investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis (AAV). Methods This multicenter cohort study designed to emulate a target trial studied 296 patients with AAV treated with rituximab or ...
Yun Kyu Kim   +7 more
wiley   +1 more source

Purification of the glucocorticoid receptor from rat liver cytosol.

open access: hybrid, 1979
Örjan Wränge   +2 more
openalex   +1 more source

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease‐modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK‐pot" study)

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF‐inhibitors (TNFi) or biologic Disease‐Modifying Anti‐Rheumatic Drugs with other modes of action (bDMARD‐OMA) in a multi‐country, real‐world population.
Romain Aymon   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy